Educational, research-use-only content. This article summarizes published scientific literature for informational purposes only and is not medical advice. The compounds discussed are supplied strictly for in-vitro laboratory research and are not approved for human or veterinary use.
What is PNC-27?
PNC-27 is a synthetic peptide that joins a fragment of the p53 protein (residues 12–26) to a membrane-penetrating sequence. It is studied strictly as a laboratory anticancer-research compound (Davitt et al., 2014).
What the research examined
In cell-based studies, PNC-27 was reported to bind HDM-2 protein expressed in the membranes of cancer cells and to induce transmembrane pore formation, leading to cancer-cell necrosis — an effect described as selective for tumor cells over normal cells in the systems tested, and independent of p53 activity. The cited work examined a human leukemia cell line (K562) and used normal leukocytes as a control (Davitt et al., 2014).
How it is thought to work
The proposed mechanism centers on PNC-27’s interaction with membrane-bound HDM-2 in cancer cells, forming pores that cause cell death — a membrane-targeting concept being explored in cancer-cell biology (Davitt et al., 2014).
The limits of the current evidence
- This is in-vitro / cell-line research only. It is not evidence of a treatment, and there are no approved human uses.
- PNC-27 is supplied strictly for in-vitro laboratory research use and is not for human use.
References
According to PubMed:
- Davitt K, et al. The anti-cancer peptide PNC-27 induces tumor cell necrosis dependent on membrane HDM-2 expression. Ann Clin Lab Sci. 2014. PMID:25117093
